AG-014699
Hereditary Breast Ovarian Cancer Syndrome
Explore 8 assets in Hereditary Breast Ovarian Cancer Syndrome →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Cancer Research UK
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00664781CT.gov Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hereditary Breast Ovarian Cancer Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| AG-014699 (this asset) | Cancer Research UK | P2 | B · 57 |
| Olaparib | VA Office of Research and Development | P3 | BB |
| Carboplatin | VA Office of Research and Development | P2 | BB |
| Letrozole | UNICANCER | P3 | BB |
| Veliparib | AbbVie | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | University Health Network, Toronto | P2/3 | BB |
| Metformin | Alliance for Clinical Trials in Oncology | P3 | B |
| Tamoxifen | The Cleveland Clinic | P2 | B |
| Adriamycin | Barretos Cancer Hospital | P2 | B |
+17 more in the Hereditary Breast Ovarian Cancer Syndrome cohort
Other indications for AG-014699
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| BRCA2-Related Cancer Predisposition | — | P2 | B · 57 |
| Breast Cancer | — | P2 | CCC · 48 |
| Ovarian Cancer | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. AG-014699 in Hereditary Breast Ovarian Cancer Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ag-014699-hereditary-breast-ovarian-cancer-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →